Investor Relations

Back a global-first in dementia neuro-therapeutics.

We are engaging a select group of qualified investors and strategic partners to advance the SynBD Phase 3 program. The full confidential briefing is shared on request.

The Opportunity, In Brief

A pivotal study, materially de-risked.

SynBD is a synthetic, THC-free cannabidiol candidate. Its pivotal study is designed to be the largest randomised trial globally evaluating a synthetic CBD therapeutic for dementia, in collaboration with Universiti Putra Malaysia.

Double-blind RCT ICH-GCP Ethics clearance in final stages Sites pre-identified CRO engaged Cost-efficient setting Clean IP profile

The confidential briefing covers the clinical protocol, regulatory pathway, manufacturing strategy, market model, use of proceeds and terms. It is provided to qualified parties under the understanding that it is confidential and not for distribution.

Access is granted to qualified investors and strategic partners following review of each request.

Request the briefing

Tell us who you are and we'll be in touch.